Journal
PROTEOMICS CLINICAL APPLICATIONS
Volume 4, Issue 12, Pages 883-887Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.201000113
Keywords
Biomarker qualification; Mass spectrometry; Multiple reaction monitoring; Selected reaction monitoring
Ask authors/readers for more resources
Proteomics has long been thought to hold the promise of producing results of clinical utility which will influence patient treatment and outcomes. A recent Wellcome Trust/EBI meeting and retreat - Perspectives in Clinical Proteomics - brought together experts from a broad range of stakeholder groups with an interest in ensuring proteomics achieves this aim. This viewpoint presents views derived from these forums, proposing a pathway for the development of next-generation proteomic analyses in the clinical setting from selection of candidates through to their validation and ultimate demonstration of utility through health technology assessments. Although not meant to be all encompassing, important elements for proteomics researchers to consider are presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available